This should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatmentThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearDuration of timepatients willtakeabemaciclib inearly stagediseasePreferredfrequencyof GnRHagonistsThis drugclass are thebackbone ofHR+ diseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score 1%This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classPreferredregimen forHR+ diseasefor frail/elderlypatientsThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agentshould beinitiated withneratinib for thefirst 8 weeksThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Based onOncotype DX,a score of 35will receivethis treatmentThis agent canbe added toLN+ HER2+disease givenwithtrastuzumabI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearDuration of timepatients willtakeabemaciclib inearly stagediseasePreferredfrequencyof GnRHagonistsThis drugclass are thebackbone ofHR+ diseaseThis agent cancauseendometrialcancer, but hasbone densityprotective effectThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationPatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyBased onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score 1%This agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression The onlysteroidalaromataseinhibitor in itsdrug classPreferredregimen forHR+ diseasefor frail/elderlypatientsThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate The ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis treatmentmodality isalwayscombined withlumpectomysurgeryUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis agentshould beinitiated withneratinib for thefirst 8 weeksThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trial

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. This should be monitored routinely every 3-4 months while receiving trastuzumab
  2. Based on Oncotype DX, a score of 35 will receive this treatment
  3. This agent can be added to LN+ HER2+ disease given with trastuzumab
  4. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  5. Duration of time patients will take abemaciclib in early stage disease
  6. Preferred frequency of GnRH agonists
  7. This drug class are the backbone of HR+ disease
  8. This agent can cause endometrial cancer, but has bone density protective effect
  9. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  10. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  11. Patients with HER2+ disease continue targeted therapy for this duration
  12. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  13. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  14. 1%
  15. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression
  16. The only steroidal aromatase inhibitor in its drug class
  17. Preferred regimen for HR+ disease for frail/elderly patients
  18. This subtype of breast cancer has the lowest relative 5-year survival rate
  19. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  20. This treatment modality is always combined with lumpectomy surgery
  21. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  22. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  23. This agent should be initiated with neratinib for the first 8 weeks
  24. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial